Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]
- Market Cap ₹ 4,26,254 Cr.
- Current Price ₹ 1,777
- High / Low ₹ 1,910 / 1,547
- Stock P/E 36.9
- Book Value ₹ 324
- Dividend Yield 0.90 %
- ROCE 20.2 %
- ROE 16.9 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 23.8% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 33.8%
Cons
- The company has delivered a poor sales growth of 9.87% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Sensex Nifty 50 BSE 500 BSE Healthcare BSE 100
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16,080 | 27,392 | 28,487 | 31,578 | 26,489 | 29,066 | 32,838 | 33,498 | 38,654 | 43,886 | 48,497 | 52,578 | 54,964 | |
| 9,078 | 19,498 | 20,313 | 21,476 | 20,858 | 22,689 | 25,855 | 25,028 | 28,397 | 32,235 | 35,479 | 37,464 | 38,410 | |
| Operating Profit | 7,003 | 7,894 | 8,174 | 10,102 | 5,631 | 6,377 | 6,983 | 8,470 | 10,258 | 11,650 | 13,018 | 15,114 | 16,554 |
| OPM % | 44% | 29% | 29% | 32% | 21% | 22% | 21% | 25% | 27% | 27% | 27% | 29% | 30% |
| -1,968 | 283 | -42 | 610 | -135 | -258 | 382 | -3,449 | -3,505 | 459 | 865 | 1,444 | 517 | |
| Interest | 44 | 579 | 523 | 400 | 518 | 555 | 303 | 141 | 127 | 172 | 238 | 231 | 275 |
| Depreciation | 409 | 1,195 | 1,038 | 1,265 | 1,500 | 1,753 | 2,053 | 2,080 | 2,144 | 2,529 | 2,557 | 2,575 | 2,724 |
| Profit before tax | 4,581 | 6,403 | 6,571 | 9,048 | 3,479 | 3,810 | 5,010 | 2,799 | 4,481 | 9,408 | 11,088 | 13,752 | 14,071 |
| Tax % | 15% | 14% | 14% | 13% | 26% | 16% | 16% | 18% | 24% | 9% | 13% | 20% | |
| 3,879 | 5,476 | 5,658 | 7,846 | 2,542 | 3,208 | 4,172 | 2,272 | 3,389 | 8,513 | 9,610 | 10,965 | 10,485 | |
| EPS in Rs | 15.17 | 21.92 | 18.89 | 29.03 | 8.73 | 11.11 | 15.69 | 12.10 | 13.64 | 35.32 | 39.91 | 45.55 | 43.56 |
| Dividend Payout % | 10% | 14% | 5% | 12% | 23% | 25% | 25% | 62% | 73% | 33% | 34% | 35% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 11% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 24% |
| 3 Years: | 20% |
| TTM: | 3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 25% |
| 3 Years: | 21% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 16% |
| 3 Years: | 17% |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 207 | 207 | 241 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
| Reserves | 18,318 | 25,431 | 32,742 | 36,400 | 38,074 | 41,169 | 45,025 | 46,223 | 47,771 | 55,755 | 63,427 | 71,978 | 77,580 |
| 2,561 | 8,996 | 8,497 | 9,832 | 10,385 | 10,514 | 8,315 | 3,869 | 1,290 | 6,886 | 3,274 | 2,362 | 5,215 | |
| 8,009 | 14,089 | 13,948 | 14,624 | 15,598 | 12,666 | 14,615 | 17,291 | 20,474 | 17,831 | 18,387 | 17,328 | 20,672 | |
| Total Liabilities | 29,095 | 48,723 | 55,428 | 61,095 | 64,297 | 64,590 | 68,194 | 67,622 | 69,776 | 80,712 | 85,328 | 91,908 | 103,706 |
| 6,817 | 12,682 | 15,872 | 17,675 | 18,853 | 21,837 | 22,847 | 21,553 | 22,665 | 24,065 | 23,248 | 22,586 | 33,371 | |
| CWIP | 842 | 2,039 | 2,175 | 2,801 | 2,465 | 1,411 | 1,220 | 1,567 | 1,287 | 4,973 | 5,354 | 6,644 | 1,355 |
| Investments | 2,786 | 2,716 | 1,830 | 1,192 | 7,143 | 7,903 | 10,143 | 9,612 | 12,849 | 14,824 | 15,026 | 18,354 | 19,543 |
| 18,650 | 31,286 | 35,550 | 39,427 | 35,837 | 33,439 | 33,984 | 34,890 | 32,975 | 36,849 | 41,700 | 44,324 | 49,438 | |
| Total Assets | 29,095 | 48,723 | 55,428 | 61,095 | 64,297 | 64,590 | 68,194 | 67,622 | 69,776 | 80,712 | 85,328 | 91,908 | 103,706 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3,959 | 5,616 | 6,686 | 7,082 | 3,907 | 2,196 | 6,555 | 6,170 | 8,985 | 4,959 | 12,135 | 14,072 | |
| -2,176 | -1,502 | -3,949 | -4,186 | -3,104 | -310 | -2,225 | 407 | -5,556 | -7,220 | -763 | -5,183 | |
| 507 | -1,187 | -1,889 | -2,285 | -1,539 | -2,731 | -5,715 | -5,980 | -5,193 | 2,376 | -6,710 | -7,906 | |
| Net Cash Flow | 2,290 | 2,927 | 848 | 611 | -736 | -844 | -1,386 | 596 | -1,765 | 115 | 4,662 | 983 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 50 | 68 | 87 | 83 | 108 | 112 | 105 | 99 | 99 | 95 | 85 | 91 |
| Inventory Days | 410 | 307 | 370 | 307 | 338 | 366 | 311 | 378 | 315 | 360 | 338 | 348 |
| Days Payable | 174 | 178 | 207 | 197 | 234 | 192 | 142 | 167 | 158 | 194 | 194 | 210 |
| Cash Conversion Cycle | 286 | 197 | 251 | 193 | 212 | 285 | 274 | 310 | 255 | 261 | 229 | 228 |
| Working Capital Days | 71 | -7 | 37 | -4 | -31 | 31 | 51 | 51 | 47 | 40 | 55 | 65 |
| ROCE % | 34% | 23% | 18% | 20% | 10% | 10% | 10% | 13% | 17% | 16% | 17% | 20% |
Documents
Announcements
-
Intimation Under Regulation 30 - Approval Of Proposal For Greenfield Project
2 Dec - Board approved INR 3,000 crore greenfield formulations facility in Madhya Pradesh (02-Dec-2025).
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1 Dec - Sun Pharma launches ILUMYA in India for moderate-to-severe plaque psoriasis; Indian study showed PASI75 up to 93.9%
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
26 Nov - FDA approves UNLOXCYT label update; CK-301-101 (n=109) shows ≥50% ORR; launch early 2026.
-
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
22 Nov - Certified NCLT order filed; Composite Scheme effective 22 Nov 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
17 Nov - Sun Pharma and AstraZeneca to promote/distribute SZC (Lokelma/Gimliand) in India; announced 17 Nov 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
Concalls
-
Nov 2025TranscriptPPTREC
-
Sep 2025Transcript PPT REC
-
Jul 2025TranscriptAI SummaryPPT
-
May 2025TranscriptPPTREC
-
Mar 2025Transcript PPT
-
Jan 2025TranscriptAI SummaryPPTREC
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptAI SummaryPPT
-
Sep 2024TranscriptAI SummaryPPT
-
Aug 2024Transcript PPT REC
-
May 2024TranscriptPPT
-
Mar 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptPPT
-
Jan 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptPPT
-
Sep 2023TranscriptAI SummaryPPT
-
Aug 2023Transcript PPT
-
May 2023TranscriptPPTREC
-
Apr 2023TranscriptAI SummaryPPT
-
Feb 2023Transcript PPT
-
Nov 2022TranscriptPPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptPPT
-
Jun 2022TranscriptPPT
-
Mar 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
Product Offerings
The company produces a range of generic and specialty medications for chronic and acute conditions. Its product portfolio includes generics, branded generics, specialty pharmaceuticals, advanced technology-based products, antiretrovirals, active pharmaceutical ingredients (APIs), and intermediates. It offers medications in multiple dosage forms, such as injectables, sprays, ointments, creams, liquids, tablets, and capsules. [1] [2]The company offers 26+ products in the global specialty market, with a strategic focus on dermatology, ophthalmology, and onco-dermatology segments. [3]